Skip To Main Content
Sara Freeman on Muck Rack

Sara Freeman

As seen in: TIME, The Atlantic, Medscape, Medscape France, Medscape Noticias Médicas, Notebook, Literary Hub, Powell's Books Blog, MDEdge, MDedge Dermatology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sara

Contact Sara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pregnancy Registry Offers Reassurance on Dupilumab

|
By Sara Freeman
| Medscape Verified
VIENNA — Dupilumab (Dupixent) was not associated with an increased risk for major structural birth defects or other adverse pregnancy and infant outcomes in a prospective registry involving women treated for atopic dermatitis or asthma.
Open in Who Shared Issue with article?

Triple-Targeting Tilrekimig Eases Established Eczema in Early Trial

|
By Sara Freeman
| Medscape Verified
TOPLINE Once-monthly treatment with the investigational trispecific antibody tilrekimig was associated with high clinical response rates in people with eczema, including itch improvement. METHODOLOGY Tilrekimig simultaneously targets three cytokines that are important for type 2 inflammatory pathways: interleukin (IL)-4, IL-13, and thymic stromal lymphopoietin. This broad approach could be better than disease control using single cytokine-targeting therapies, such as dupilumab.
Open in Who Shared Issue with article?

ADtouch Results: Hand and Foot Eczema Responds Well to Lebrikizumab

|
By Sara Freeman
| Medscape Verified
VIENNA — More than half of all patients with moderate-to-severe atopic dermatitis of the hands and feet treated with lebrikizumab (Ebglyss) monotherapy in a phase 3b trial achieved the primary endpoint of clear or almost clear skin. Additionally, significant reductions were seen in itch and pain caused by the eczematous lesions, and more than three quarters of lebrikizumab-treated patients said they were satisfied or very satisfied with the degree of skin clearance on their hands at week 16.
Open in Who Shared Issue with article?
See all 205 articles